Effective Date: August 21, 2023

TEST CHANGE

Apolipoprotein B/A Ratio

0050028, APO B/A

0050028, APC	J B/A				
Specimen Rec	quirements:				
Patient Pre	eparation:		Fasting sp	pecimen recommended.	
Collect:			Serum sep heparin-	parator tube <u>, plasma separator tube, K2EDTA, lithium</u>	
Specimen I	Preparation:		Separate s	cimen to clot completely at room temperature. serum <u>or plasma</u> from cells ASAP or within 2 hours of . Transfer 1 mL serum <u>or plasma</u> to an ARUP <u>transport tube.</u> Standard Transport Tube. (Min: 0.5	
Transport 1	Temperature:		Refrigerat	ed.	
Unacceptal	ble Conditions	s:	Hemolyze	d specimens.	
Remarks:					
Stability:				aration from cells: Ambient: <u>24</u> 8 hours; Refrigerated: 8 zen: <u>2</u> 3 months	
Methodology:			Quantitati	ve <u>Immunoturbidimetry</u> Nephelometry	
Performed:			Sun-Sat		
Reported:			Within 24	hours	
Note:					
CPT Codes:			82172 x2		
New York DOI	H Approval Sta	atus:	This test is	s New York DOH approved.	
Interpretive Da	ata:				
•				r-1 can provide an estimate of the relative-risk for ecoronary atherosclerotic disease.	
Relative Risk: Apolipoprotein B/A Ratio:-1	Male	Fema	ale		
Low <mark>One Half Average</mark> Risk	0. <u>2 - 0.6</u> 4	0.3			
MediumAverage Risk	1.0	0. <u>61</u> -	- 0.909		
<u>High</u> Twice Average Risk	1.6	0.91 -	<u>-</u> 1.5 <u>.0</u>		

Effective Date: August 21, 2023

Reference Interval:

Test Number	Components	Reference Int	Reference Interval		
	Apolipoprotein B				
		Male	Female		
		55-140 mg/dL	55-125 mg/dL		
	Apolipoprotein A-1				
		Male	Female		
		94-178 mg/dL	101-199 mg/dL		